MetaCap

Vera Therapeutics (VERA) vs Zymeworks (ZYME)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Zymeworks (ZYME) has outperformed Vera Therapeutics (VERA) over the past year, gaining 8.8% versus a loss of 10.6%. Over five years, ZYME leads with a +34.1% price change compared with -15.2% for VERA. Vera Therapeutics is the larger company by market cap ($1.84 billion vs $1.81 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

VERA-10.58%ZYME+8.83%
+101%+43%-16%
Nov 21, 20251 yearNov 20, 2026
VERA-18.43%ZYME+31.95%
+79%-5%-90%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

VERA versus ZYME key metrics
MetricVERAZYME
Share price$25.45$26.14
Market cap$1.84B$1.81B
1-day change-4.86%-2.68%
YTD return-49.74%-0.72%
1-year return-10.58%+8.83%
5-year return-15.17%+34.05%
P/E ratio (TTM)—49.32
Forward P/E—54.95
EPS (TTM)$-5.90$0.53
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$105.97M
Revenue growth (YoY)—+38.87%
Net income (latest FY)$-299.62M$-81.13M
Operating margin—-87.34%
Net margin—-76.56%
52-week high$56.05$31.97
52-week low$25.08$21.52
Distance from 52-week high-54.59%-18.24%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+180.39%+65.61%
Average volume1.95M1.09M
Shares outstanding72.30M68.70M
Employees362279
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ZYME has outperformed VERA by 19.4 percentage points over the past year.

About Vera Therapeutics

VERA stock →

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 362 employees

About Zymeworks

ZYME stock →

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.

Health Care · Biotechnology: Pharmaceutical Preparations · 279 employees

VERA vs ZYME FAQ

Which is bigger, Vera Therapeutics or Zymeworks?

Vera Therapeutics (VERA) is larger, with a market capitalization of $1.84B compared with $1.81B for Zymeworks (ZYME).

Which stock has performed better over the past year, VERA or ZYME?

ZYME returned +8.83% over the past 12 months, compared with -10.58% for VERA (price return, excluding dividends). Past performance does not predict future results.

Are Vera Therapeutics and Zymeworks in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons